Summary
A briefing prompted by a Mushies Facebook post about a clinical trial of inhaled 5-MeO-DMT for postpartum depression. The post is accurate: it reports a real, peer-reviewed Phase 2a open-label trial of GH001 (inhaled mebufotenin, a pharmaceutical 5-MeO-DMT) published 4 June 2026 in The Journal of Clinical Psychiatry. Ten women with moderate-to-severe postpartum depression all reached remission within two hours of a single day of dosing, sustained through Day 8, with no serious adverse events and breast-milk clearance within ~8 hours. The headline result is genuinely striking — but it is an early-stage, uncontrolled pilot (N=10, no placebo, 8-day follow-up), and open-label psychedelic trials almost always look more dramatic than the controlled data that follows. What lends it credibility is the same compound's placebo-controlled Phase 2b win in treatment-resistant depression. This briefing separates what is solid from what is hype, and places it in the wider postpartum-depression treatment landscape.
Key points
- The compound: GH001 is an inhaled (vaporized) formulation of 5-MeO-DMT — a fast-acting, short-duration psychedelic tryptamine, in drug-development contexts now called mebufotenin. It is a synthesized, pharmaceutical-grade product, not toad venom. Developed by GH Research (Ireland-based, NASDAQ: GHRS).
- The key selling point is duration, not novelty. Each dose produces a psychoactive window of only ~20–25 minutes, so patients can be dosed and discharged the same day — unlike psilocybin (6+ hours) or a brexanolone infusion (60 hours).
- The trial (NCT05804708): Phase 2a, single-arm, open-label. 10 women, aged 18–45 (mean 31.6), 4 weeks–12 months postpartum, mean baseline MADRS 36.7. Conducted March 2023–August 2024. Lead author Dr. Kristina M. Deligiannidis (Northwell Health), a leading PPD researcher who also worked on brexanolone and zuranolone.
- Dosing: Three escalating doses on a single day — 6 mg, then 12 mg, then 18 mg — at 1-hour intervals, individualized by tolerability and psychoactive response. No accompanying psychotherapy.
- Efficacy: 100% remission (10/10, MADRS ≤10) achieved within two hours and sustained through Day 8. Mean MADRS reduction −35.4 points (P<0.0001). Maternal functioning (Barkin Index) up 56%. No treatment-emergent suicidal ideation.
- Safety: 13 treatment-emergent adverse events across 8 of 10 patients, mostly mild (headache most common). No serious adverse events, no withdrawals.
- Breastfeeding data (the practically important bit): Mebufotenin in breast milk peaked at 0.24–3.11 ng/mL at 1 hour and was undetectable by ~8 hours; bufotenin was undetectable; the 5-MIAA metabolite cleared by Day 8. This supports only a brief interruption of breastfeeding around dosing.
- The honest caveats: N=10, no control arm, no blinding, only 8 days of follow-up, 90% White population. A 100% remission rate in an open-label psychedelic trial is exactly the kind of result that shrinks under placebo control. The authors themselves frame it as justification for "larger, randomized, placebo-controlled trials" — that is the correct framing.
- Why it is not dismissible as hype: The same compound hit its primary endpoint in a placebo-controlled Phase 2b treatment-resistant-depression trial: −15.5-point placebo-adjusted MADRS reduction, 57.5% remission vs 0% placebo at Day 8, and 77.8% still in remission at 6 months. That Phase 2b was published in JAMA Psychiatry, which makes the underlying antidepressant mechanism credible rather than speculative.
- The treatment landscape it enters: PPD options each carry friction. SSRIs take weeks. Brexanolone (Zulresso) required a 60-hour in-hospital IV infusion and was withdrawn from the US market in April 2025. Zuranolone (Zurzuvae) is oral but a 14-day course. A single-day, rapid-onset option is meaningfully different — if the efficacy holds up under controls.
- Bottom line: A real and exciting result, correctly described by the Facebook post, but an early uncontrolled pilot. Watch for the randomized, placebo-controlled PPD trial — that is the result that will actually settle it.
Fact check
The claims in this briefing are drawn from the primary sources above (the peer-reviewed paper, the company press releases, and the trial registry). Spot-checks on the highest-stakes figures:
| Claim | Verdict | Notes | Source |
|---|---|---|---|
| "All ten patients achieved remission within two hours, sustained through Day 8" | ✅ Confirmed | 100% remission (10/10, MADRS ≤10) within 2 hours and maintained through Day 8 is reported as a primary finding. | J Clin Psychiatry paper; GH Research release |
| "Mean MADRS reduction was −35.4 points (P<0.0001)" | ✅ Confirmed | Reported as the primary endpoint result, baseline to Day 8. | GH Research release |
| "Dosing was 6, 12, and 18 mg on a single day at 1-hour intervals" | ✅ Confirmed | Three escalating doses, individualized by tolerability and psychoactive response. | J Clin Psychiatry paper |
| "No serious adverse events; AEs mostly mild; headache most common" | ✅ Confirmed | 13 TEAEs in 8 of 10 patients, 87.5% mild, no SAEs, no withdrawals, no treatment-emergent suicidal ideation. | J Clin Psychiatry paper |
| "Breast-milk levels cleared within ~8 hours" | ✅ Confirmed | Mebufotenin 0.24–3.11 ng/mL at 1 hour, undetectable by ~8 hours; supports only a brief interruption of breastfeeding around dosing. | J Clin Psychiatry paper |
| "N=10, open-label, no control arm, 8-day follow-up" | ✅ Confirmed | The trial's own stated design and limitations: small sample, no blinding, no placebo, short follow-up, predominantly White. | J Clin Psychiatry paper; NCT05804708 |
| "The same compound won a placebo-controlled Phase 2b in TRD" | ✅ Confirmed | −15.5-point placebo-adjusted MADRS reduction, 57.5% remission vs 0% placebo at Day 8, 77.8% in remission at 6 months; published in JAMA Psychiatry. | GH Research Phase 2b release; Psychiatric Times |
| "Brexanolone was withdrawn from the US market in April 2025" | ✅ Confirmed | No longer commercially available as of 1 Jan 2025; FDA approval withdrawn as of 14 Apr 2025. | Obstetrics & Gynecology (2026) |
| "GH001 is synthesized 5-MeO-DMT, not toad venom" | ✅ Confirmed | GH Research synthesizes mebufotenin and formulates it for inhalation; it is a pharmaceutical product, not derived from Bufo alvarius. | 5-MeO-DMT (Wikipedia); GH Research pipeline |
Related resources
| Type | Name | URL | Notes |
|---|---|---|---|
| press release | GH Research — Publication of Phase 2a PPD Results (4 Jun 2026) | https://www.globenewswire.com/news-release/2026/06/04/3306645/0/en/gh-research-announces-publication-of-phase-2a-postpartum-depression-results.html | The official announcement with headline numbers |
| 📄 | Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression — J Clin Psychiatry | https://www.psychiatrist.com/jcp/inhaled-mebufotenin-gh001-postpartum-depression-phase-2a-open-label-trial/ | The peer-reviewed Phase 2a paper (DOI: 10.4088/JCP.25m16284) |
| 🔗 | ClinicalTrials.gov — NCT05804708 | https://clinicaltrials.gov/study/NCT05804708 | The trial registry record |
| 🔗 | 5-MeO-DMT — Wikipedia | https://en.wikipedia.org/wiki/5-MeO-DMT | Pharmacology and background on the compound |
| 📄 | Psychedelic therapy and postpartum depression: priorities and prospects (PMC) | https://pmc.ncbi.nlm.nih.gov/articles/PMC12972557/ | Field-level context on psychedelics for PPD |
| press release | GH Research — Phase 2b TRD Primary Endpoint Met (−15.5 placebo-adjusted MADRS) | https://investor.ghres.com/news-releases/news-release-details/gh-research-announces-primary-endpoint-met-phase-2b-trial-gh001/ | The placebo-controlled result that lends credibility |
| 📄 | GH Research — Phase 2b TRD results published in JAMA Psychiatry | https://investor.ghres.com/news-releases/news-release-details/gh-research-announces-publication-phase-2b-results-mebufotenin/ | Peer-reviewed Phase 2b in TRD |
| 🗞️ | Positive Results in Phase 2b Trial of GH001 for TRD — Psychiatric Times | https://www.psychiatrictimes.com/view/positive-results-in-phase-2b-trial-of-psychedelic-agent-gh001-for-treatment-resistant-depression | Independent coverage of the Phase 2b |
| 📄 | Zuranolone and Brexanolone for the Treatment of PPD — Obstetrics & Gynecology (2026) | https://journals.lww.com/greenjournal/fulltext/2026/01000/zuranolone_and_brexanolone_for_the_treatment_of.22.aspx | The current neurosteroid landscape |
| 🔗 | GH Research — Pipeline | https://www.ghres.com/our-work/pipeline | Company development pipeline |
Full content
(click to expand)
Is the Facebook post real?
Yes. The Mushies post describes a Phase 2a open-label trial of inhaled 5-MeO-DMT (GH001 / mebufotenin) for postpartum depression, published 4 June 2026 in The Journal of Clinical Psychiatry (DOI 10.4088/JCP.25m16284), led by Dr. Kristina Deligiannidis at Northwell Health. Every headline figure in the post — ten patients, full remission, ~96% symptom reduction by Day 8, 56% improvement in maternal functioning, suicidal ideation falling to zero, no serious adverse events, same-day discharge, effects within two hours — checks out against the paper and the company's announcement. This is not a fabricated or exaggerated viral claim; the underlying study is real.
What the compound actually is
5-MeO-DMT is a naturally occurring psychedelic tryptamine, found in the venom of the Colorado River toad (Bufo alvarius) and in some plants. GH001 is not toad venom: it is synthesized, pharmaceutical-grade 5-MeO-DMT (now called mebufotenin in drug-development contexts) formulated by GH Research for delivery as a vapor through a proprietary inhalation device. Its defining pharmacological feature is brevity — the intense psychoactive experience lasts only about 20–25 minutes per dose. That is the entire commercial thesis: an antidepressant psychedelic experience short enough to dose-and-discharge in a single clinic visit, rather than the 6+ hours psilocybin requires or the multi-day infusions older PPD drugs needed.
What the trial found
Ten women with moderate-to-severe postpartum depression (mean baseline MADRS 36.7) received three escalating doses — 6 mg, 12 mg, 18 mg — on a single day, an hour apart, with the dose individualized to tolerability. All ten reached remission (MADRS ≤10) within two hours, and all ten were still in remission at Day 8, for a mean reduction of 35.4 points. Maternal functioning rose 56% on the Barkin Index. Adverse events were mild and transient (headache most common), with no serious events and no new suicidal ideation. Breast-milk analysis found the drug undetectable by roughly eight hours, supporting only a brief pause in breastfeeding around dosing rather than a prolonged interruption.
Why to be excited — and why to be careful
The careful part first: this is a ten-person, open-label, uncontrolled pilot with eight days of follow-up. There is no placebo group, no blinding, and the sample was 90% White. A 100% remission rate is exactly the kind of result that tends to deflate once a placebo arm is added, because expectancy effects in psychedelic trials are large and well-documented. The authors say as much — they frame the study as justification for larger randomized placebo-controlled trials, not as proof of a treatment.
The exciting part: this is not an isolated small study from an unknown group. The same compound, GH001, already met its primary endpoint in a placebo-controlled Phase 2b trial in treatment-resistant depression — a −15.5-point placebo-adjusted MADRS reduction, 57.5% remission versus 0% on placebo at Day 8, and 77.8% of patients still in remission at six months — and that Phase 2b was published in JAMA Psychiatry. A placebo-controlled win on the same molecule is what elevates the PPD pilot from "probably noise" to "plausible signal worth a real trial."
The landscape it would enter
Postpartum depression treatment has real gaps. SSRIs work but take weeks. Brexanolone (Zulresso) demonstrated that a rapid neurosteroid could help, but it required a 60-hour in-hospital IV infusion and was withdrawn from the US market in April 2025. Zuranolone (Zurzuvae), approved in 2023, is oral and now the preferred neurosteroid option, but it is still a 14-day course. Against that backdrop, a single-day, rapid-onset, dose-and-discharge treatment is a genuinely different shape of intervention — which is precisely why it is worth taking seriously enough to demand the controlled trial that would prove it.
Bottom line
The Facebook post is accurate and the result is genuinely promising. But it is an early, uncontrolled pilot, and the responsible reading is: striking signal, not yet a treatment. The placebo-controlled Phase 2b in TRD is what makes it credible rather than hype. The number to watch for is the randomized, placebo-controlled PPD trial — that is the one that will settle whether this is a breakthrough or a beautiful open-label artifact.